Revenue and Related Matters - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Transaction Price Allocated to Remaining Performance Obligations | ||||||
| Contract assets | $ 0.0 | $ 0.0 | $ 0.0 | |||
| Revenue | 4.7 | $ 3.1 | 8.2 | $ 5.6 | ||
| Amount of transaction price allocated to performance obligations | 17.4 | 17.4 | ||||
| Akoya Biosciences, Inc. | ||||||
| Transaction Price Allocated to Remaining Performance Obligations | ||||||
| Deferred revenue | $ 7.9 | |||||
| Undelivered licenses of intellectual property | ||||||
| Transaction Price Allocated to Remaining Performance Obligations | ||||||
| Amount of transaction price allocated to performance obligations | 2.5 | 2.5 | ||||
| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-07-01 | ||||||
| Transaction Price Allocated to Remaining Performance Obligations | ||||||
| Amount of transaction price allocated to performance obligations | $ 14.9 | $ 14.9 | ||||
| Performance obligation satisfaction period | 12 months | 12 months | ||||